Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

21.02.25 22:05 Uhr

Werte in diesem Artikel
Aktien

278,80 EUR -8,30 EUR -2,89%

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015.

Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

 "We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."

Mr. Kassing is President Emeritus of San Jose State University. Mr. Kassing served as President of San Jose State University from 2004 to 2008, Interim President from 2010 to 2011, and Vice President, Administration and Finance and Chief Financial Officer from 1993 to 2004. Prior to his tenure at San Jose State University, Mr. Kassing spent 18 years in higher education and 11 years in private industry, including eight years in merchandising/marketing and operations management at Caleres, Inc. (formerly known as the Brown Group, Inc.), a leading footwear retailer and wholesaler, and spent 3 years in corporate finance at the General Motors Corporation. Mr. Kassing received a B.A. and an M.B.A. from Saint Louis University.

About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on InstagramLinkedIn and X.

Investor Relations
Penumbra, Inc.
investors@penumbrainc.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-announces-don-kassing-will-retire-from-board-of-directors-302382448.html

SOURCE Penumbra, Inc.

Ausgewählte Hebelprodukte auf Penumbra

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Penumbra

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Penumbra Inc

Wer­bung

Analysen zu Penumbra Inc

DatumRatingAnalyst
15.12.2017Penumbra Market PerformBMO Capital Markets
24.10.2016Penumbra OutperformBMO Capital Markets
30.11.2015Penumbra BuyCanaccord Adams
DatumRatingAnalyst
15.12.2017Penumbra Market PerformBMO Capital Markets
24.10.2016Penumbra OutperformBMO Capital Markets
30.11.2015Penumbra BuyCanaccord Adams
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Penumbra Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"